Aceto Corporation (ACET) News
Filter ACET News Items
ACET News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACET News Highlights
- ACET's 30 day story count now stands at 4.
- Over the past 7 days, the trend for ACET's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO and MRNS are the most mentioned tickers in articles about ACET.
Latest ACET News From Around the Web
Below are the latest news stories about Adicet Bio Inc that investors may wish to consider to help them evaluate ACET as an investment opportunity.
Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover CandidateAdicet Bio (ACET) was founded in 2014 and is based in Boston, Massachusetts. The company’s platform is based on gamma delta T cells, which have been major investor attention recently. The first generation of CAR T therapies was based on alpha beta T cells and had issues with durability and... |
Analysts Are Bullish on These Healthcare Stocks: Adicet Bio (ACET), Marinus (MRNS)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adicet Bio (ACET – Research Report) and Marinus (MRNS – Research Report) with bullish sentiments. Adicet Bio (ACET) H.C. Wainwright analyst Edward White reiterated a Buy rating on Adicet Bio today and set a price target of $35.00. The company's shares closed last Thursday at $12.13. According to TipRanks. |
JMP Securities Remains a Buy on Adicet Bio (ACET)In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Adicet Bio (ACET – Research Report), with a price target of $30.00. The company's shares closed last Thursday at $12.30. According to TipRanks.com, Benjamin is ranked 0 out of 5 stars with an average return of -12.0% and a 31.8% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adicet Bio with a $32.00 average price target, a 158.1% upside from current levels. |
Adicet Bio to Participate in Guggenheim 2022 Oncology ConferenceMENLO PARK, Calif. & BOSTON, February 02, 2022--Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2022 Oncology Conference taking place virtually on February 9-11, 2022. |
Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesMENLO PARK, Calif. and BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 937,500 shares of common stock, at a pub |
How a biotech is turning 'road bikes' into 'mountain bikes' to roll over cancerAdicet Bio Inc.'s secret is out. With a first-mover advantage in an emerging niche of cancer cell therapy and promising interim data from an early-stage clinical study, the Menlo Park company's stock has jumped as much as 61% since last Friday's close. What's more, the company is moving into a 50,305-square-foot facility in Redwood City with the goal of pushing a new therapy into clinical trials every 12 to 18 months. |
Adicet Bio, Inc. Announces Pricing of Public Offering of Common StockMENLO PARK, Calif. and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $14.00 per share. Adicet also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stoc |
Analysts’ Top Healthcare Picks: Biohaven Pharmaceutical Holding Co (BHVN), Adicet Bio (ACET)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biohaven Pharmaceutical Holding Co (BHVN – Research Report), Adicet Bio (ACET – Research Report) and Kazia Therapeutics (KZIA – Research Report) with bullish sentiments. Biohaven Pharmaceutical Holding Co (BHVN) In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Biohaven Pharmaceutical Holding Co, with a price target of $160.00. The company's shares closed last Monday at $100.24. According to TipRanks. |
Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common StockMENLO PARK, Calif. and BOSTON, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced that it has commenced an underwritten public offering of its common stock. Adicet also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold at the public offering price, less underwriting |
Adicet Bio (ACET) Received its Third Buy in a RowAfter H.C. Wainwright and JMP Securities gave Adicet Bio (NASDAQ: ACET) a Buy rating last month, the company received another Buy, this time from JonesTrading. Analyst Soumit Roy reiterated a Buy rating on Adicet Bio today and set a price target of $33.00. The company's shares closed last Friday at $9.80. According to TipRanks.com, Roy is a 5-star analyst with an average return of 20.3% and a 34.6% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals. Adicet Bio has an analyst consensus of Strong Buy, with a price target consensus of $30.75. |